Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4060874 · 1 trial · 1 indication
Number of participants with one or more TEAEs and SAEs.
| Arm | Type | Description |
|---|---|---|
| LY4060874 (Part A Subcutaneous) | EXPERIMENTAL | Single ascending dose of LY4060874 administered subcutaneously (SC). |
| LY4060874 (Part A Intravenous) | EXPERIMENTAL | Single ascending dose of LY4060874 administered intravenously (IV). |
| LY4060874 (Part B) | EXPERIMENTAL | Multiple ascending doses of LY4060874 administered SC. |
| LY4060874 (Part B Chinese) | EXPERIMENTAL | Multiple ascending doses of LY4060874 administered SC in Chinese participants. |
| LY4060874 (Part C Japanese) | EXPERIMENTAL | Multiple ascending doses of LY4060874 administered SC in Japanese participants. |
| Placebo (SC) | PLACEBO_COMPARATOR | Placebo administered SC in Part A, B, and C. |
| Placebo (IV) | PLACEBO_COMPARATOR | Placebo administered IV in Part A. |
| Name | Type | Description |
|---|---|---|
| LY4060874 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation, including medical history and physical examination. * Have a body mass index in the range of 20 to 29.9 kilogram per meter squared (kg/m²), inclusive, at screening. * To qualify as Chinese for this study, all 4 of the pa...
LY4060874 is an investigational small molecule being studied in healthy participants. It is being evaluated in a Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetics. The drug is not approved for any medical condition and is currently in early-stage clinical development.
LY4060874 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The company is conducting clinical research on this investigational small molecule in healthy participants.
LY4060874 is in Phase 1 clinical development. The Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities and is still undergoing early-stage clinical evaluation.
LY4060874 has one completed Phase 1 clinical trial, identified as NCT06709820, titled "A Study of LY4060874 in Healthy Participants." This randomized, double-blind, placebo-controlled study enrolled 121 participants in the United States and Singapore.
LY4060874 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial in healthy participants. The drug is still in clinical development and has not been authorized for use in any medical condition.